Enkang Pharmaceutical Technology

Enkang Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, dedicated to developing innovative small molecule therapeutics for oncology. The company focuses on addressing significant unmet medical needs in cancer treatment, particularly for liver cancer and other solid tumors. Its lead clinical candidate, ENK-001, is a multi-target kinase inhibitor currently being evaluated in Phase 2 clinical trials for hepatocellular carcinoma. Enkang utilizes a proprietary drug discovery platform to identify and optimize novel compounds with improved efficacy and safety profiles. The leadership team consists of experienced scientists and industry veterans committed to advancing global health through precision medicine. The company aims to bridge the gap between laboratory research and clinical application to provide affordable and effective treatments.